LIBRETTO-431

NCT04194944 📎

Regimen

Experimental
selpercatinib
Control
platinum+pemetrexed ± pembrolizumab

Population

RET fusion+ advanced NSCLC 1L

Key finding

mPFS 24.8 vs 11.2 mo, HR 0.46 (0.31-0.70); RET-TKI 1L confirmed

Source: PMID 37870973

Timeline

  • Enrollment start: 2020-02-17 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.215)
  • CSCO NSCLC 2025 ⚠️ OCR source